Patent intelligence · US
US 11654157
Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation
Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in comb…
Patent details — US 11654157
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 23, 2023
- Expiration
- May 18, 2043
- Applicant
- Shuttle Pharmaceuticals, Inc.
- Claims
- 10
- CPC classes
- A61K, A61K2121/00, A61K31/513, A61K31/7072
Quick answer
US 11654157 (Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation) is held by Shuttle Pharmaceuticals, Inc.. Status: granted. Granted May 23, 2023. Expires May 18, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Shuttle Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K2121/00, A61K31/513, A61K31/7072, A61K33/243, A61P
More from Shuttle Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12357650
Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorlylase inhibitors in combination with radiation
granted -
US 12077515
Selective histone deacetylase inhibitors for the treatment of human disease
granted -
US 11584733
Selective histone deacetylase inhibitors for the treatment of human disease
granted -
US 11407723
Selective histone deacetylase inhibitors for the treatment of human disease
granted -
US 11034667
Selective histone deacetylase inhibitors for the treatment of human disease
granted -
US 10745352
Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof
granted -
US 10730834
Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof
granted
Frequently asked questions
What is US patent 11654157?
US 11654157 (Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation) is held by Shuttle Pharmaceuticals, Inc.. Status: granted. Granted May 23, 2023. Expires May 18, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11654157?
Shuttle Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.
When does US 11654157 expire?
Our index shows an expiration date of May 18, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.